MK-2214
Objective: Slow early Alzheimer's disease progression
- Age 50-85
- Early Alzheimer's Disease
- Infusion
Objective: Slow early Alzheimer's disease progression
Objective: Evaluating a new treatment for early Alzheimer's
Objective: Assess delaying of the progression to symptomatic stages
Objective: Evaluating a treatment for cognitive impairment in AD
Let us help you find the right trial! We'll guide you through the selection process and connect you with trials that best fit your profile and needs.